Blog

Research studies for new treatments offer hope for glaucoma patients

Breakthrough Glaucoma Treatments Offer New Hope for Patients Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. For years, treatment options were limited to eye drops, laser therapy, and invasive surgeries. However, recent advancements in medical science are revolutionizing how we manage this condition. Today, breakthrough glaucoma treatments […]

Research studies for new treatments offer hope for glaucoma patients Read More »

Open Angle Glaucoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight

Open Angle Glaucoma Clinical Trials 2025: FDA, EMA, and NICE Approvals Open-angle glaucoma (OAG) remains one of the leading causes of irreversible blindness worldwide. With an aging population and increasing prevalence, the demand for innovative treatments is higher than ever. The year 2025 is poised to be a landmark period for OAG clinical trials, with

Open Angle Glaucoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight Read More »

Researchers developing ‘minimally invasive’ glaucoma treatments

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops and invasive surgeries, have limitations, including side effects and variable efficacy. However, recent advancements in medical technology are paving the way for minimally invasive glaucoma treatments (MIGS) that promise

Researchers developing ‘minimally invasive’ glaucoma treatments Read More »

Sanoculis wins CE mark for minimally invasive glaucoma treatment device

# Sanoculis Secures CE Mark for Innovative Glaucoma Treatment Device ## Introduction In a significant milestone for ophthalmic innovation, **Sanoculis** has recently obtained the **CE Mark** for its groundbreaking glaucoma treatment device. This regulatory approval paves the way for the commercialization of their cutting-edge technology in **Europe**, offering new hope for patients suffering from this

Sanoculis wins CE mark for minimally invasive glaucoma treatment device Read More »

Army Hospital introduces 3D microscope for minimally invasive glaucoma surgery –

Army Hospital Pioneers 3D Microscope for Glaucoma Surgery Breakthroughs In a groundbreaking development, an Army hospital has introduced a cutting-edge 3D microscope to revolutionize glaucoma surgery. This innovative technology promises to enhance precision, improve surgical outcomes, and reduce recovery times for patients suffering from this sight-threatening condition. With glaucoma affecting millions worldwide, this advancement could

Army Hospital introduces 3D microscope for minimally invasive glaucoma surgery – Read More »

Reimagining Indian Healthcare

Transforming Indian Healthcare for a Brighter Future The Indian healthcare system has come a long way, yet challenges persist. With a growing population, increasing healthcare demands, and the need for equitable access, India stands at a critical juncture. Transforming Indian healthcare is not just a necessity—it’s an opportunity to build a healthier, more prosperous nation.

Reimagining Indian Healthcare Read More »

Pilocarpine eye drops improve outcomes after Kahook Dual Blade goniotomy surgery

# Pilocarpine Eye Drops Enhance Results After Kahook Dual Blade Goniotomy ## Introduction Glaucoma is a leading cause of irreversible blindness worldwide, and surgical interventions like the Kahook Dual Blade (KDB) goniotomy have emerged as effective treatments to lower intraocular pressure (IOP). However, recent studies suggest that combining KDB with pilocarpine eye drops can further

Pilocarpine eye drops improve outcomes after Kahook Dual Blade goniotomy surgery Read More »

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Sight Sciences Announces Q1 2025 Financial Results on May 8 Sight Sciences, Inc., a leading innovator in ophthalmology and optometry, has announced that it will release its Q1 2025 financial results on May 8, 2025. This eagerly anticipated update will provide insights into the company’s performance, growth trajectory, and strategic initiatives in the first quarter

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 Read More »

Treating Glaucoma Has Evolved in Patients, Physicians Alike: Christine Funke, MD

# Evolution of Glaucoma Treatment: Advancements for Patients and Physicians Glaucoma, often referred to as the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. Over the years, the treatment of glaucoma has evolved significantly, offering patients and physicians more effective and less invasive options. From ancient remedies to cutting-edge surgical techniques,

Treating Glaucoma Has Evolved in Patients, Physicians Alike: Christine Funke, MD Read More »

Glaucoma, retina, and ophthalmic industry topics kickstart the ASCRS and ASOA Annual Meetings

# Top Glaucoma and Retina Trends at ASCRS & ASOA Annual Meetings The ASCRS & ASOA Annual Meetings are among the most anticipated events in ophthalmology, bringing together leading experts to discuss groundbreaking advancements in eye care. This year, the spotlight was on glaucoma and retina treatments, with innovative technologies, surgical techniques, and pharmaceutical developments

Glaucoma, retina, and ophthalmic industry topics kickstart the ASCRS and ASOA Annual Meetings Read More »

Scroll to Top